Requip (ropinirole), the SECOND new drug for Parkinson's to hit the market

November 1997

SmithKline Beecham is now marketing Requip (ropinirole), the SECOND new drug for Parkinson's to hit the market this year.

The first one, Mirapex (pramipexole) was approved in July.

Requip and Mirapex are second-generation dopamine agonists.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote